Associations of digital neuro-signatures with molecular and neuroimaging measures of brain resilience: The altoida large cohort study

被引:3
作者
Seixas, Azizi [1 ]
Rajabli, Farid A. [2 ]
Pericak-Vance, Margaret [2 ]
Jean-Louis, Girardin L. [1 ]
Tarnanas, Ioannis [3 ,4 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL USA
[3] Altoida Inc, Washington, DC USA
[4] Global Brain Hlth Inst, Trinity Coll Dublin, Dublin, Ireland
来源
FRONTIERS IN PSYCHIATRY | 2022年 / 13卷
基金
美国国家卫生研究院;
关键词
digital biomarker; dementia; cognitive impairment; Alzheimer's disease; cognitive resilience; ALZHEIMERS-DISEASE; COGNITION; MEMORY;
D O I
10.3389/fpsyt.2022.899080
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
BackgroundMixed results in the predictive ability of traditional biomarkers to determine cognitive functioning and changes in older adults have led to misdiagnosis and inappropriate treatment plans to address mild cognitive impairment and dementia among older adults. To address this critical gap, the primary goal of the current study is to investigate whether a digital neuro signature (DNS-br) biomarker predicted global cognitive functioning and change over time relative among cognitively impaired and cognitive healthy older adults. The secondary goal is to compare the effect size of the DNS-br biomarker on global cognitive functioning compared to traditional imaging and genomic biomarkers. The tertiary goal is to investigate which demographic and clinical factors predicted DNS-br in cognitively impaired and cognitively healthy older adults. MethodsWe conducted two experiments (Study A and Study B) to assess DNS for brain resilience (DNS-br) against the established FDG-PET brain imaging signature for brain resilience, based on a 10 min digital cognitive assessment tool. Study A was a semi-naturalistic observational study that included 29 participants, age 65+, with mild to moderate mild cognitive impairment and AD diagnosis. Study B was also a semi-naturalistic observational multicenter study which included 496 participants (213 mild cognitive impairment (MCI) and 283 cognitively healthy controls (HC), a total of 525 participants-cognitively healthy (n = 283) or diagnosed with MCI (n = 213) or AD (n = 29). ResultsDNS-br total score and majority of the 11 DNS-br neurocognitive subdomain scores were significantly associated with FDG-PET resilience signature, PIB ratio, cerebral gray matter and white matter volume after adjusting for multiple testing. DNS-br total score predicts cognitive impairment for the 80+ individuals in the Altoida large cohort study. We identified a significant interaction between the DNS-br total score and time, indicating that participants with higher DNS-br total score or FDG-PET in the resilience signature would show less cognitive decline over time. ConclusionOur findings highlight that a digital biomarker predicted cognitive functioning and change, which established biomarkers are unable to reliably do. Our findings also offer possible etiologies of MCI and AD, where education did not protect against cognitive decline.
引用
收藏
页数:15
相关论文
共 40 条
  • [1] Relationships Between Tau and Glucose Metabolism Reflect Alzheimer's Disease Pathology in Cognitively Normal Older Adults
    Adams, Jenna N.
    Lockhart, Samuel N.
    Li, Lexin
    Jagust, William J.
    [J]. CEREBRAL CORTEX, 2019, 29 (05) : 1997 - 2009
  • [2] Coupled changes in hippocampal structure and cognitive ability in later life
    Anblagan, Devasuda
    Hernandez, Maria C. Valdes
    Ritchie, Stuart J.
    Aribisala, Benjamin S.
    Royle, Natalie A.
    Hamilton, Iona F.
    Cox, Simon R.
    Gow, Alan J.
    Pattie, Alison
    Corley, Janie
    Starr, John M.
    Maniega, Susana Munoz
    Bastin, Mark E.
    Deary, Ian J.
    Wardlaw, Joanna M.
    [J]. BRAIN AND BEHAVIOR, 2018, 8 (02):
  • [3] 2021 Alzheimer's disease facts and figures
    不详
    [J]. ALZHEIMERS & DEMENTIA, 2021, 17 (03) : 327 - 406
  • [4] [Anonymous], 2021, BIGEN LAUNCH PIONEER
  • [5] Clinical utility of FDG-PET for the clinical diagnosis in MCI
    Arbizu, Javier
    Festari, Cristina
    Altomare, Daniele
    Walker, Zuzana
    Bouwman, Femke
    Rivolta, Jasmine
    Orini, Stefania
    Barthel, Henryk
    Agosta, Federica
    Drzezga, Alexander
    Nestor, Peter
    Boccardi, Marina
    Frisoni, Giovanni Battista
    Nobili, Flavio
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (09) : 1497 - 1508
  • [6] The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies
    Arenaza-Urquijo, Eider M.
    Przybelski, Scott A.
    Lesnick, Timothy L.
    Graff-Radford, Jonathan
    Machulda, Mary M.
    Knopman, David S.
    Schwarz, Christopher G.
    Lowe, Val J.
    Mielke, Michelle M.
    Petersen, Ronald C.
    Jack, Clifford R., Jr.
    Vemuri, Prashanthi
    [J]. BRAIN, 2019, 142 : 1134 - 1147
  • [7] Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease
    Arnold, Steven E.
    Louneva, Natalia
    Cao, Kajia
    Wang, Li-San
    Han, Li-Ying
    Wolk, David A.
    Negash, Selamawit
    Leurgans, Sue E.
    Schneider, Julie A.
    Buchman, Aron S.
    Wilson, Robert S.
    Bennett, David A.
    [J]. NEUROBIOLOGY OF AGING, 2013, 34 (01) : 157 - 168
  • [8] Babrak Lmar M, 2019, Digit Biomark, V3, P92, DOI 10.1159/000502000
  • [9] Digital biomarker-based individualized prognosis for people at risk of dementia
    Buegler, Maximilian
    Harms, Robbert L.
    Balasa, Mircea
    Meier, Irene B.
    Exarchos, Themis
    Rai, Laura
    Boyle, Rory
    Tort, Adria
    Kozori, Maha
    Lazarou, Eutuxia
    Rampini, Michaela
    Cavaliere, Carlo
    Vlamos, Panagiotis
    Tsolaki, Magda
    Babiloni, Claudio
    Soricelli, Andrea
    Frisoni, Giovanni
    Sanchez-Valle, Raquel
    Whelan, Robert
    Merlo-Pich, Emilio
    Tarnanas, Ioannis
    [J]. ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2020, 12 (01)
  • [10] Developing and adopting safe and effective digital biomarkers to improve patient outcomes
    Coravos, Andrea
    Khozin, Sean
    Mandl, Kenneth D.
    [J]. NPJ DIGITAL MEDICINE, 2019, 2 (1)